Bracco Group has announced the sale of Esaote S.p.A. to a consortium of investors led by Banca Intesa. In addition to Banca Intesa, the consortium includes IMI Investimenti, the investment company Equinox, Mps Venture, Banca Carige and a group of managers headed by Carlo Castellano, current chairman and CEO of Esaote, according to a release.
The sale of Esaote, which represents the unit of the Bracco Group dedicated to biomedical equipment, "is part of our strategy to develop our core business, that is, contrast agents and therapeutic products, focusing on new products in the molecular diagnostic and targeted therapy fields," said Diana Bracco, president and CEO, Bracco Spa. "In addition to strengthen our direct presence in the international markets, we are redefining our identity, in order to present ourselves to the markets as a consistent, highly-technological Group in the advanced medical diagnostics field," Bracco added.
The transaction is part of Banca Intesa's strategy aimed at sustaining Italy's development by supporting entrepreneurs who invest in innovation and long-term growth also via the acquisition of equity stakes.
"Esaote is an extremely successful industrial and technological entity in the Italian research panorama. One of Banca Intesa's missions is to sustain Italian companies which are sound from an industrial standpoint, have considerable technological competencies and are significant in terms of employment," said Corrado Passera, managing director and CEO, Banca Intesa SpA. "We are therefore proud of our contribution to the further development of companies like Esaote, which operate in sectors with a high technological content, with important production and research and development units in Liguria and Tuscany and strongly projected in the international markets," Passera added.